A systematic overview of radiation therapy effects in ovarian cancer
(2003) In Acta Oncologica 42(5-6). p.562-566- Abstract
- A systematic review of radiation therapy trials in several tumour types was performed by The Swedish Council of Technology Assessment in Health Care (SBU). The procedures for evaluation of the scientific literature are described separately (Acta Oncol 2003; 42: 357-365). This synthesis of the literature on radiation therapy for ovarian cancer is based on data from six randomized trials. Moreover, data from one prospective study and three retrospective studies were used. In total, 10 scientific articles are included, involving 1282 patients. The results were compared with those of a similar overview from 1996 including 15042 patients. The conclusions reached can be summarized in the following points: There is no scientific documentation... (More)
- A systematic review of radiation therapy trials in several tumour types was performed by The Swedish Council of Technology Assessment in Health Care (SBU). The procedures for evaluation of the scientific literature are described separately (Acta Oncol 2003; 42: 357-365). This synthesis of the literature on radiation therapy for ovarian cancer is based on data from six randomized trials. Moreover, data from one prospective study and three retrospective studies were used. In total, 10 scientific articles are included, involving 1282 patients. The results were compared with those of a similar overview from 1996 including 15042 patients. The conclusions reached can be summarized in the following points: There is no scientific documentation supporting adjuvant radiotherapy for early-stage, low-risk patients. No studies have been reported where adjuvant radiotherapy has been compared with no adjuvant therapy in early-stage, high-risk patients. Adjuvant radiotherapy, either whole abdominal irradiation or intraperitoneal p(32), has been compared with adjuvant chemotherapy in early-stage, high-risk patients. There is no scientific evidence to show that there is a difference in efficacy. There is some evidence to suggest that adjuvant radiotherapy after radical surgery leads to an increase in disease-free survival rate for patients with advanced-stage ovarian cancer. There is little documentation on long-term side effects (second malignancy) after adjuvant radiotherapy and no conclusions can be drawn. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/299612
- author
- Einhorn, N ; Trope, C ; Ridderheim, Mona LU ; Boman, K ; Sorbe, B and Cavallin-Ståhl, Eva LU
- organization
- publishing date
- 2003
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Acta Oncologica
- volume
- 42
- issue
- 5-6
- pages
- 562 - 566
- publisher
- Taylor & Francis
- external identifiers
-
- wos:000185767900016
- pmid:14596514
- scopus:0141525461
- ISSN
- 1651-226X
- DOI
- 10.1080/02841860310014426
- language
- English
- LU publication?
- yes
- id
- d7aa5832-a199-4727-b146-298f670f58dc (old id 299612)
- date added to LUP
- 2016-04-01 15:23:06
- date last changed
- 2022-01-28 05:05:11
@article{d7aa5832-a199-4727-b146-298f670f58dc,
abstract = {{A systematic review of radiation therapy trials in several tumour types was performed by The Swedish Council of Technology Assessment in Health Care (SBU). The procedures for evaluation of the scientific literature are described separately (Acta Oncol 2003; 42: 357-365). This synthesis of the literature on radiation therapy for ovarian cancer is based on data from six randomized trials. Moreover, data from one prospective study and three retrospective studies were used. In total, 10 scientific articles are included, involving 1282 patients. The results were compared with those of a similar overview from 1996 including 15042 patients. The conclusions reached can be summarized in the following points: There is no scientific documentation supporting adjuvant radiotherapy for early-stage, low-risk patients. No studies have been reported where adjuvant radiotherapy has been compared with no adjuvant therapy in early-stage, high-risk patients. Adjuvant radiotherapy, either whole abdominal irradiation or intraperitoneal p(32), has been compared with adjuvant chemotherapy in early-stage, high-risk patients. There is no scientific evidence to show that there is a difference in efficacy. There is some evidence to suggest that adjuvant radiotherapy after radical surgery leads to an increase in disease-free survival rate for patients with advanced-stage ovarian cancer. There is little documentation on long-term side effects (second malignancy) after adjuvant radiotherapy and no conclusions can be drawn.}},
author = {{Einhorn, N and Trope, C and Ridderheim, Mona and Boman, K and Sorbe, B and Cavallin-Ståhl, Eva}},
issn = {{1651-226X}},
language = {{eng}},
number = {{5-6}},
pages = {{562--566}},
publisher = {{Taylor & Francis}},
series = {{Acta Oncologica}},
title = {{A systematic overview of radiation therapy effects in ovarian cancer}},
url = {{http://dx.doi.org/10.1080/02841860310014426}},
doi = {{10.1080/02841860310014426}},
volume = {{42}},
year = {{2003}},
}